Nycomed Announces REACT Study To Evaluate Impact Of Daxas(R) (roflumilast) In Patients Receiving Standard COPD Treatment
Links shared publicly online about this topic.
- 401total visits
Nycomed Announces REACT Study To Evaluate Impact Of Daxas(R) (roflumilast) In Patients Receiving Standard COPD Treatment
Nycomed announced plans for an international phase III/IV study investigating the effect of Daxas® (500mcg tablets, once daily) versus placebo on exacerbation rates in COPD patients who are co
View full resource at medicalnewstoday.com
Most Recently Shared on March 30, 2011 at 4:05 pm By:
Nycomed Announces REACT Study To Evaluate Impact Of Daxas(R) (roflumilast) In Patients Receiving Standard COPD Treatment http://mnt.to/3SVT
Advertisement
